Last reviewed · How we verify
Henggliflozin
Henggliflozin is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. It is currently FDA-approved.
Henggliflozin is a medication being studied for the treatment of conditions including Diabetes Mellitus, Type 2, Myocardial Infarction, Heart Failure, and Polycystic Ovary Syndrome. It is being compared to a placebo and Henagliflozin in clinical trials, with one study specifically examining its effects on glucose fluctuation and immunosenescence in Type 2 diabetes patients on insulin therapy.
At a glance
| Generic name | Henggliflozin |
|---|---|
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction (PHASE4)
- The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy (PHASE4)
- SGLT2 Inhibitors in Treating Patients With PCOS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Henggliflozin CI brief — competitive landscape report
- Henggliflozin updates RSS · CI watch RSS
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI
Frequently asked questions about Henggliflozin
What is Henggliflozin?
Who makes Henggliflozin?
What development phase is Henggliflozin in?
Related
- Manufacturer: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing